Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$87.77
3.193.77%
al cierre: -
$87.77
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Inspire Medical Systems Inc ha un obiettivo di prezzo di consenso pari a $196.59, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da Leerink Partners, Leerink Partners y Truist Securities il agosto 15, 2025, agosto 5, 2025 y agosto 5, 2025. Con un obiettivo di prezzo medio di $112.67 tra le Leerink Partners, Leerink Partners y Truist Securities, c'è un implicito 28.37% upside per Inspire Medical Systems Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Leerink Partners
Truist Securities
Lake Street
Wells Fargo
UBS
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Inspire Medical Systems
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/15/2025 | 10.52% | Leerink Partners | $116 → $97 | Maintains | Market Perform | |||
08/05/2025 | 32.16% | Leerink Partners | $149 → $116 | Maintains | Market Perform | |||
08/05/2025 | 42.42% | Truist Securities | $190 → $125 | Downgrade | Buy → Hold | |||
08/05/2025 | 70.9% | Lake Street | $270 → $150 | Maintains | Buy | |||
08/05/2025 | 15.07% | Wells Fargo | $174 → $101 | Maintains | Equal-Weight | |||
08/05/2025 | 162.05% | UBS | $270 → $230 | Maintains | Buy | |||
08/05/2025 | 105.08% | RBC Capital | $215 → $180 | Maintains | Outperform | |||
08/05/2025 | 59.51% | Stifel | $175 → $140 | Maintains | Hold | |||
08/05/2025 | 70.9% | Piper Sandler | $233 → $150 | Maintains | Overweight | |||
08/05/2025 | 25.33% | JP Morgan | $195 → $110 | Downgrade | Overweight → Neutral | |||
08/05/2025 | — | Keybanc | — | Downgrade | Overweight → Sector Weight | |||
07/22/2025 | 124.45% | Keybanc | $216 → $197 | Maintains | Overweight | |||
07/15/2025 | 107.36% | Morgan Stanley | $200 → $182 | Maintains | Overweight | |||
07/14/2025 | 69.76% | Leerink Partners | $176 → $149 | Maintains | Market Perform | |||
05/06/2025 | 127.87% | Morgan Stanley | $220 → $200 | Maintains | Overweight | |||
05/06/2025 | 122.17% | JP Morgan | $235 → $195 | Maintains | Overweight | |||
05/06/2025 | 98.25% | Wells Fargo | $195 → $174 | Maintains | Equal-Weight | |||
05/06/2025 | 168.88% | Baird | $230 → $236 | Maintains | Outperform | |||
05/05/2025 | 100.52% | Leerink Partners | $194 → $176 | Maintains | Market Perform | |||
04/21/2025 | 99.38% | Stifel | $190 → $175 | Maintains | Hold | |||
04/21/2025 | 146.1% | Keybanc | $234 → $216 | Maintains | Overweight | |||
04/15/2025 | 144.96% | RBC Capital | $260 → $215 | Maintains | Outperform | |||
02/11/2025 | 121.03% | Leerink Partners | $193 → $194 | Maintains | Market Perform | |||
02/11/2025 | 167.75% | Truist Securities | $250 → $235 | Maintains | Buy | |||
02/11/2025 | 196.23% | RBC Capital | $260 → $260 | Reiterates | Outperform → Outperform | |||
02/11/2025 | 182.56% | Baird | $252 → $248 | Maintains | Outperform | |||
02/11/2025 | 122.17% | Wells Fargo | $198 → $195 | Maintains | Equal-Weight | |||
02/11/2025 | 150.66% | Morgan Stanley | $230 → $220 | Maintains | Overweight | |||
02/10/2025 | 165.47% | Piper Sandler | $260 → $233 | Maintains | Overweight | |||
01/24/2025 | 166.61% | Keybanc | $236 → $234 | Reiterates | Overweight → Overweight | |||
01/21/2025 | 116.47% | Stifel | $200 → $190 | Maintains | Hold | |||
11/20/2024 | 190.53% | B of A Securities | $220 → $255 | Upgrade | Neutral → Buy | |||
11/05/2024 | 184.84% | Truist Securities | $240 → $250 | Maintains | Buy | |||
11/05/2024 | 162.05% | Morgan Stanley | $210 → $230 | Maintains | Overweight | |||
11/05/2024 | 196.23% | RBC Capital | $260 → $260 | Reiterates | Outperform → Outperform | |||
11/05/2024 | 196.23% | Piper Sandler | $255 → $260 | Reiterates | Overweight → Overweight | |||
11/05/2024 | 127.87% | Stifel | $170 → $200 | Reiterates | Hold → Hold | |||
11/05/2024 | 125.59% | Wells Fargo | $187 → $198 | Maintains | Equal-Weight | |||
11/05/2024 | 187.11% | Baird | $240 → $252 | Maintains | Outperform | |||
09/30/2024 | 173.44% | Truist Securities | $217 → $240 | Reiterates | Buy → Buy | |||
09/10/2024 | 124.45% | Leerink Partners | $167 → $197 | Maintains | Market Perform | |||
08/07/2024 | 168.88% | Keybanc | $278 → $236 | Maintains | Overweight | |||
08/07/2024 | 196.23% | RBC Capital | $260 → $260 | Reiterates | Outperform → Outperform | |||
08/07/2024 | 127.87% | Baird | $220 → $200 | Maintains | Outperform | |||
07/16/2024 | 147.24% | Truist Securities | $280 → $217 | Maintains | Buy | |||
07/15/2024 | 139.26% | Morgan Stanley | $250 → $210 | Maintains | Overweight | |||
06/24/2024 | 93.69% | Stifel | $210 → $170 | Maintains | Hold | |||
06/03/2024 | 110.78% | B of A Securities | $225 → $185 | Maintains | Neutral | |||
05/08/2024 | 190.53% | Piper Sandler | $250 → $255 | Maintains | Overweight | |||
04/19/2024 | 224.71% | RBC Capital | → $285 | Initiates | → Outperform | |||
03/27/2024 | 184.84% | Mizuho | $250 → $250 | Maintains | Buy | |||
03/20/2024 | 219.02% | Truist Securities | → $280 | Reiterates | Buy → Buy | |||
03/19/2024 | 184.84% | Morgan Stanley | → $250 | Initiates | → Overweight | |||
02/07/2024 | 219.02% | Truist Securities | $265 → $280 | Maintains | Buy | |||
02/07/2024 | 184.84% | Mizuho | $225 → $250 | Maintains | Buy | |||
02/06/2024 | 216.74% | Keybanc | → $278 | Initiates | → Overweight | |||
01/19/2024 | 179.14% | Jefferies | — | → $245 | Initiates | → Buy | ||
01/02/2024 | 139.26% | Stifel | → $210 | Downgrade | Buy → Hold | |||
12/22/2023 | 196.23% | Truist Securities | $240 → $260 | Maintains | Buy | |||
12/13/2023 | 113.06% | Wells Fargo | → $187 | Downgrade | Overweight → Equal-Weight | |||
11/08/2023 | 139.26% | Stifel | $250 → $210 | Maintains | Buy | |||
11/08/2023 | 144.96% | Mizuho | $300 → $215 | Maintains | Buy | |||
11/08/2023 | 173.44% | Truist Securities | $260 → $240 | Maintains | Buy | |||
11/08/2023 | 179.14% | Wells Fargo | $330 → $245 | Maintains | Overweight | |||
11/07/2023 | 184.84% | Stifel | $350 → $250 | Maintains | Buy | |||
10/17/2023 | 106.22% | JP Morgan | $340 → $181 | Maintains | Overweight | |||
10/16/2023 | 81.16% | Leerink Partners | → $159 | Initiates | → Market Perform | |||
10/02/2023 | 287.38% | Truist Securities | → $340 | Reiterates | Buy → Buy | |||
09/06/2023 | 266.87% | UBS | $405 → $322 | Maintains | Buy | |||
08/24/2023 | 287.38% | Truist Securities | $363 → $340 | Maintains | Buy | |||
08/02/2023 | 287.38% | JP Morgan | $300 → $340 | Maintains | Overweight | |||
08/02/2023 | 298.77% | Lake Street | $305 → $350 | Maintains | Buy | |||
08/02/2023 | 313.58% | Truist Securities | $380 → $363 | Maintains | Buy | |||
08/02/2023 | 275.98% | Wells Fargo | $315 → $330 | Maintains | Overweight | |||
07/19/2023 | 332.95% | Truist Securities | $360 → $380 | Maintains | Buy | |||
07/19/2023 | 322.7% | Baird | → $371 | Initiates | → Outperform | |||
07/13/2023 | 298.77% | Stifel | $300 → $350 | Maintains | Buy | |||
07/05/2023 | 304.47% | B of A Securities | $310 → $355 | Maintains | Buy | |||
06/12/2023 | 241.8% | Mizuho | → $300 | Reiterates | Buy → Buy | |||
06/08/2023 | 287.38% | Piper Sandler | $315 → $340 | Maintains | Overweight | |||
06/08/2023 | 281.68% | Keybanc | $321 → $335 | Maintains | Overweight | |||
05/18/2023 | 310.16% | Piper Sandler | $335 → $360 | Maintains | Overweight | |||
05/03/2023 | 246.36% | UBS | $300 → $304 | Maintains | Buy | |||
05/03/2023 | 258.89% | Piper Sandler | $305 → $315 | Maintains | Overweight | |||
05/03/2023 | 265.73% | Keybanc | $303 → $321 | Maintains | Overweight | |||
04/14/2023 | 241.8% | Mizuho | → $300 | Initiates | → Buy | |||
04/13/2023 | 241.8% | Mizuho | → $300 | Initiates | → Buy | |||
04/11/2023 | 241.8% | Stifel | $290 → $300 | Maintains | Buy | |||
03/29/2023 | 241.8% | UBS | → $300 | Initiates | → Buy | |||
02/08/2023 | 275.98% | Truist Securities | $310 → $330 | Maintains | Buy | |||
02/08/2023 | 241.8% | JP Morgan | $271 → $300 | Maintains | Overweight | |||
02/08/2023 | 247.5% | Piper Sandler | $300 → $305 | Maintains | Overweight | |||
01/31/2023 | 253.2% | Truist Securities | $308 → $310 | Maintains | Buy | |||
01/26/2023 | 241.8% | Piper Sandler | $285 → $300 | Maintains | Overweight | |||
01/13/2023 | 245.22% | Keybanc | $287 → $303 | Maintains | Overweight | |||
12/20/2022 | 250.92% | Truist Securities | $270 → $308 | Maintains | Buy | |||
12/13/2022 | — | Goldman Sachs | — | Upgrade | Neutral → Buy | |||
12/13/2022 | 226.99% | Keybanc | → $287 | Initiates | → Overweight | |||
10/17/2022 | 173.44% | Truist Securities | $280 → $240 | Maintains | Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Inspire Medical Systems (INSP)?
El último precio objetivo de Inspire Medical Systems (NYSE:INSP) fue comunicado por Leerink Partners el agosto 15, 2025. La firma de analistas fijó un precio objetivo para $97.00 que espera INSP a rise dentro de 12 meses (un posible 10.52% upside). 41 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Inspire Medical Systems (INSP)?
La última calificación de analistas para Inspire Medical Systems (NYSE:INSP) fue proporcionada por Leerink Partners, y Inspire Medical Systems mantuvo su market perform calificación.
¿Cuándo se produjo la última revisión al alza de Inspire Medical Systems (INSP)?
La última revisión al alza de Inspire Medical Systems Inc se produjo en noviembre 20, 2024, cuando B of A Securities elevó su precio objetivo a $255. B of A Securities anteriormente tenía a neutral para Inspire Medical Systems Inc.
¿Cuándo fue la última revisión a la baja de Inspire Medical Systems (INSP)?
La última revisión a la baja de Inspire Medical Systems Inc se produjo en agosto 5, 2025, cuando Truist Securities cambió su precio objetivo de $190 a $125 para Inspire Medical Systems Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Inspire Medical Systems (INSP)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Inspire Medical Systems, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Inspire Medical Systems se registró el agosto 15, 2025, por lo que la próxima calificación estará disponible en torno al agosto 15, 2026.
¿Es correcta la calificación de los analistas sobre Inspire Medical Systems (INSP)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Inspire Medical Systems (INSP) fue un mantuvo con un precio objetivo de $116.00 a $97.00. El precio actual al que cotiza Inspire Medical Systems (INSP) es de $87.77, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.